Business

Alexza Pharmaceuticals has announced that it plans to reacquire US rights for Adasuve loxapine inhalation powder from Teva Pharmaceuticals USA by January 1, 2016. According to the company, "Alexza and Teva are working on a transition agreement to continue product availability to patients and health care providers after the return of the rights to Alexza." Adasuve … [Read more...] about Alexza to reacquire US rights to Adasuve from Teva

AstraZeneca Canada has announced the availability of the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI in Canada for the treatment of COPD. Health Canada issued a Notice of Compliance for Duaklir Genuair on April 2, 2015. AstraZeneca acquired Canadian rights to Duaklir Genuair from Actavis in February 2015. In Europe, the inhaler was approved for the … [Read more...] about AstraZeneca launches Duaklir Genuair in Canada

Glenmark Pharmaceuticals announced that it has obtained semi-exclusive rights develop and market a generic fluticasone/salmeterol DPI in 15 European countries as part of an agreement with Polish pharmaceutical company Celon Pharma. The countries covered in the deal include the UK, Germany, Norway, Sweden, and Romania. Glenmark will pay an undisclosed amount up front, … [Read more...] about Glenmark makes deal with Celon to market fluticasone/salmeterol DPI in parts of Europe

The FDA has issued a drug shortage report for Foradil Aerolizer formoterol fumarate inhalation powder due to discontinuation of the product. According to the FDA website: "Novartis (manufacturer) and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer for business reasons. It is anticipated that inventory will be exhausted and no … [Read more...] about Foradil Aerolizer discontinued

Imprimis Pharmaceuticals has announced the acquisition of what it says are the largest compounding pharmacies for sinus drugs in the US: Topical Apothecary Group, LLC (doing business as TAG Pharmacy), Aerosol Science Laboratories, Inc. (ASL Pharmacy), and SinuTopic, Inc. (Sinus Dynamics Pharmacy). Websites for all three are nearly identical, offering compounding of … [Read more...] about Imprimis Pharmaceuticals acquires intranasal formulation compounding pharmacies

Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel's Precision Olfactory Delivery (POD) platform. Impel recently announced a partnership with 3M Drug Delivery Systems for development and commercialization of the intranasal technology. Impel CEO … [Read more...] about Impel NeuroPharma gets investment from 3M New Ventures

Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the product. Alexza announced in June 2015 that it would stop manufacturing Adasuve for its partners and in September said that it was considering … [Read more...] about Ferrer affirms commitment to Adasuve

Eli Lilly has acquired worldwide rights to Locemia Solution's intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed. Lilly Diabetes President Enrique … [Read more...] about Lilly acquires Locemia’s intranasal glucagon powder